Variable clinical manifestation of a novel missense mutation in the alpha-tropomyosin (TPM1) gene in familial hypertrophic cardiomyopathy

被引:47
作者
Jongbloed, RJ
Marcelis, CL
Doevendans, PA
Schmeitz-Mulkens, JM
Van Dockum, WG
Geraedts, JP
Smeets, HJ
机构
[1] Vrije Univ Amsterdam, Med Ctr, Dept Cardiol, Amsterdam, Netherlands
[2] Interuniv Cardiol Inst Netherlands, Utrecht, Netherlands
[3] Univ Maastricht, CARIM, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[4] Univ Limburg, Acad Hosp Maastricht, Dept Clin Genet, Maastricht, Netherlands
关键词
D O I
10.1016/S0735-1097(02)03005-X
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES This study was initiated to identify the disease-causing genetic defect in a family with hypertrophic cardiomyopathy (HCM) and high incidence of sudden death. BACKGROUND Familial hypertropic cardiomyopathy (FHC) is an autosomal dominant transmitted disorder that is genetically and clinically heterogeneous. Mutations in 11 genes have been associated with the pathogenesis of the disease. METHODS We studied a large FHC family, first by linkage analysis, to identify the gene involved, and subsequently screened the gene, encoding alpha-tropomyosin (TPM1), for mutations by using single-strand conformation polymorphism and sequencing analysis. RESULTS Twelve family members presented clinical features of HCM, five of whom died at young age, while others had only mild clinical features. Marker analysis showed linkage for the TPM1 gene on chromosome 15q22 (maximal logarithm of the odds score is 5.16, theta = 0); subsequently, a novel missense mutation (Glu62Gln) was identified. CONCLUSIONS The novel mutation identified in TPM1 is associated with the clinical features of cardiac hypertrophy in all but one genetically affiected member of this large family. The clinical data suggest a malignant phenotype at young age with a variable clinical manifestation and penetrance at older age. The Glu62Gln mutation is the sixth TPM1 mutation identified as the cause of FHC, indicating that mutations in this gene are very rare. This is the first reported amino acid substitution at the f-position within the coiled-coil structure of the tropomyosin protein. (C) 2003 by the American College of Cardiology Foundation.
引用
收藏
页码:981 / 986
页数:6
相关论文
共 27 条
[11]   Identification of a gene responsible for familial Wolff-Parkinson-White syndrome [J].
Gollob, MH ;
Green, MS ;
Tang, ASL ;
Gollob, T ;
Karibe, A ;
Roberts, R ;
Ahmad, F ;
Lozado, R ;
Shah, G ;
Fananapazir, L ;
Bachinski, LL ;
Roberts, R ;
Tapscott, T ;
Gonzales, O ;
Begley, D ;
Mohiddin, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (24) :1823-1831
[12]   The cardiac β-myosin heavy chain gene is not the predominant gene for hypertrophic cardiomyopathy in the Finnish population [J].
Jääskeläinen, P ;
Soranta, M ;
Miettinen, R ;
Saarinen, L ;
Pihlajamäki, J ;
Silvennoinen, K ;
Tikanoja, T ;
Laakso, M ;
Kuusisto, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1998, 32 (06) :1709-1716
[13]  
Jongbloed RJE, 1999, HUM MUTAT, V13, P301, DOI 10.1002/(SICI)1098-1004(1999)13:4<301::AID-HUMU7>3.0.CO
[14]  
2-V
[15]  
Karibe A, 2001, CIRCULATION, V103, P65
[16]   Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy [J].
Marian, AJ .
LANCET, 2000, 355 (9197) :58-60
[17]   Hypertrophic cardiomyopathy [J].
Maron, BJ .
LANCET, 1997, 350 (9071) :127-133
[18]   Physiological consequences of tropomyosin mutations associated with cardiac and skeletal myopathies [J].
Michele, DE ;
Metzger, JM .
JOURNAL OF MOLECULAR MEDICINE-JMM, 2000, 78 (10) :543-553
[19]   Development and application of linkage analysis in genetic diagnosis of familial hypertrophic cardiomyopathy [J].
Mogensen, J ;
Andersen, PS ;
Steffensen, U ;
Christiansen, M ;
Egeblad, H ;
Gregersen, N ;
Borglum, AD .
JOURNAL OF MEDICAL GENETICS, 2001, 38 (03) :193-197
[20]  
MULLENBACH R, 1989, TRENDS GENET, V5, P391